Seed investor, Entrepreneur and Director. Involved with Xylonix from its early days when it began developing a first-in-class anti-cancer drug. We have widened our scope and are now targeting pathological macrophage immunity disorders derived from repeat infections of Covid-19, and covid vaccine side effects, which are driving up autoimmune disorders, turbocharged cancers and infectious diseases. Our products and developments comprehensively target prevention, symptomatic management and cures against these disorders.